Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen Sells 3,331 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.00, for a total transaction of $23,317.00. Following the completion of the sale, the chief executive officer now directly owns 74,123 shares in the company, valued at approximately $518,861. This represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Atara Biotherapeutics Trading Up 2.5 %

Atara Biotherapeutics stock traded up $0.18 during trading on Wednesday, hitting $7.31. 28,201 shares of the company were exchanged, compared to its average volume of 266,345. The business’s 50 day moving average is $10.09 and its 200 day moving average is $9.75. Atara Biotherapeutics, Inc. has a 52 week low of $5.40 and a 52 week high of $20.81. The company has a market capitalization of $42.11 million, a P/E ratio of -0.28 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ATRA shares. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. Canaccord Genuity Group reduced their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, January 17th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. Finally, RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Institutional Trading of Atara Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics in the 4th quarter worth about $48,000. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $169,000. Citadel Advisors LLC grew its holdings in shares of Atara Biotherapeutics by 2.6% in the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after acquiring an additional 6,873 shares in the last quarter. Bank of America Corp DE increased its position in shares of Atara Biotherapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock valued at $2,731,000 after acquiring an additional 1,543 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in Atara Biotherapeutics during the fourth quarter worth $149,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.